Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1992 - Autologous dendritic-cell vaccine based on cancer-testis antigens “CaTeVac” in the treatment of soft tissue sarcoma

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Immunology

Tumour Site

Soft Tissue Sarcomas

Presenters

Nino Pipia

Citation

Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288

Authors

N. Pipia1, I.A. Baldueva1, T.L. Nekhaeva1, A.V. Novik1, A.B. Danilova1, N.A. Avdonkina1, S.A. Protsenko2, Y.I. Komarov2, D.V. Girdyuk1, A.P. Oganesyan2, A.M. Belyaev3

Author affiliations

  • 1 Oncoimmunology, N.N. Petrov Research Institute of Oncology, 197758 - St. Petersburg/RU
  • 2 Chemotherapy And Innovative Technology, N.N. Petrov Research Institute of Oncology, 197758 - Saint Petersburg/RU
  • 3 -, N.N.Petrov Research Institute of Oncology, 197758 - St. Petersburg/RU
More

Resources

Abstract 1992

Background

Recent advances in the cancer immunotherapy provide an opportunity to develop the therapeutic autologous dendritic cell vaccine for metastatic forms of soft tissues sarcomas (STS). Previous studies showed the possibility of developing delayed effects from this treatment. The aim of this study is to compare efficacy of the 2nd line therapy of STS patients with or without CaTeVac therapy during the whole systemic treatment.

Methods

Seventy-four patients (pts.) were included since 2008 to 2017. All patients had stage III inoperable or stage IV STS and received 2nd line of systemic therapy. Group 1 received CaTeVac as adjuvant therapy or maintenance therapy after the 1st or 2nd line of systemic therapy or as monotherapy after at least 1 line of chemotherapy. Group 2 never received CaTeVac during treatment course. Patients in the groups were comparable by histologic types and previous treatment. Overall survival (OS) from the start of the 2nd line of therapy to death was assessed as efficacy measure.

Results

Median OS of patients in group 1 was 24,4 mo (741 days, 95% CI, 509-973), versus 14.2 mo (431 days, 95% CI, 56-806) in group 2 (Log-Rank p = 0.019, Breslow p = 0.03). Relative risk of death (exp(B)) in group 1 was 0,358 (95% CI 0.171-0.751) in the Cox regression and was independent from and comparable to the treatment effect (exp(B) 0.254 (95% CI 0.133-0.484), p = 0.000011. Sex and age showed no impact on survival (p > 0.05).

Conclusions

CaTeVac shows impact on overall survival and should be assessed in randomized clinical trials with OS endpoints.

Clinical trial identification

Legal entity responsible for the study

N.N. Petrov Research Institute of Oncology.

Funding

Ministry of Health Russian Federation.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.